Delivery Order SPE2DB22D1017-SPE2DB25FG9UL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Lantus SoloStar insulin (100 unit/mL, 3mL formulation) with a ceiling value of $1,022.80. This is a firm fixed-price delivery order issued without set-aside designation, indicating competitive award to the vendor. The contract is to be completed by August 21, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin on June 11, 2025, with a ceiling value of $1,917.75. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of June 12, 2025. This delivery order represents a small-value pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a $1,534.20 delivery order to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/mL insulin in 3mL quantities. The contract, executed on August 6, 2025, with an ultimate completion date of August 7, 2025, utilizes firm fixed pricing under a non-set-aside competitive procurement. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Lantus SoloStar 100 unit/mL insulin in 3 mL formulations, with a ceiling value of $2,014.04. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 25, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Lantus SoloStar 100 Unit/ML insulin in 3 mL format at a ceiling value of $1,257.96. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The order is scheduled for ultimate completion by August 14, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML insulin in 3ml quantities. This firm fixed price, competitively awarded contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single transaction executed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Lantus SoloStar 100 Unit/ML insulin in 3 mL formulations. This firm fixed-price delivery order, valued at $1,333.80, represents a non-set-aside competitive award and is part of AmerisourceBergen's broader relationship with DLA. The contract carries an ultimate completion date of August 22, 2025, with performance to be executed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,775.19 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin products. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin, a pharmaceutical product used in diabetes management. The contract, awarded on August 22, 2025, carries a ceiling value of $2,439.56 with a firm fixed-price structure and an ultimate completion date of August 25, 2025. This non-competitive delivery order represents a relatively small-value transaction typical of routine pharmaceutical replenishment under the...
- The Defense Logistics Agency awarded a $2,119.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin medication, with a completion date of August 1, 2025. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively made with no set-aside designation, and performance will...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9ULDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin medication, with a ceiling value of $1,028.38. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The contract was competitively awarded with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order falls within the broader pharmaceutical supply mission of DLA Troop Support Medical, which leverages the company's comprehensive portfolio of brand-name and generic medications, vaccines, and medical supplies to support Defense Health Agency operations and other government healthcare customers worldwide. The expedited completion timeline reflects the urgent medical supply needs typical of federal pharmaceutical procurement operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 8/14/25 |